Arcoxia advisory committee
Executive Summary
Merck announces that an FDA advisory committee will review Arcoxia (etoricoxib), its follow-on product to the withdrawn arthritis medication Vioxx. The only meeting date currently scheduled for the Arthritis Advisory Committee is April 12, 2007. The Arcoxia NDA has a user fee action date in early April 2007 following Merck's submission of a response to FDA's November 2004 "approvable" letter (1"The Pink Sheet" Nov. 13, 2006, In Brief). Merck recently raised its 2007 earnings guidance based on the assumption that Arcoxia will receive approval (2"The Pink Sheet" Dec. 11, 2006, In Brief)...